SAN DIEGO, CA--(Marketwired - Jul 1, 2013) - Adamis Pharmaceuticals Corporation ( OTCQB : ADMP ) announced today that it has completed a private placement financing transaction pursuant to which it issued senior secured convertible promissory notes and warrants to purchase up to 13,004,316 shares
SAN DIEGO, CA--(Marketwired - Jul 1, 2013) - Adamis Pharmaceuticals Corporation ( OTCQB : ADMP ) announced today that it has completed a private placement financing transaction pursuant to which it issued senior secured convertible promissory notes and warrants to purchase up to 13,004,316 shares
SAN DIEGO , May 3, 2013 /PRNewswire/ -- Dennis J. Carlo, Ph.D., the President and Chief Executive Officer of Adamis Pharmaceuticals Corporation (OTCQB: ADMP), a biopharmaceutical company engaged in the development and commercialization of specialty pharmaceutical and biotechnology
SAN DIEGO , May 3, 2013 /PRNewswire/ -- Dennis J. Carlo, Ph.D., the President and Chief Executive Officer of Adamis Pharmaceuticals Corporation (OTCQB: ADMP), a biopharmaceutical company engaged in the development and commercialization of specialty pharmaceutical and biotechnology
SAN DIEGO , Feb. 28, 2013 /PRNewswire/ -- Adamis Pharmaceuticals Corporation (OTCQB: ADMP), a biopharmaceutical company engaged in the development and commercialization of specialty pharmaceutical and biotechnology products in the therapeutic areas of respiratory disease,
SAN DIEGO , Feb. 28, 2013 /PRNewswire/ -- Adamis Pharmaceuticals Corporation (OTCQB: ADMP), a biopharmaceutical company engaged in the development and commercialization of specialty pharmaceutical and biotechnology products in the therapeutic areas of respiratory disease,
